Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02 is a research paper published in Neuro-Oncology Advances (2020). On theSindex it has a DataRank of 0. It has been cited 22 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: U01 CA06239
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: P50 CA211015
FWCI
1.01
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals